Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries

Quality of Life Research

Volumn 23, Issue 9, 2014, Pages 2645-2650

  Lauridsen, Jørgen T ^a   Lønborg, Jonas ^b   Gundgaard, Jens ^c   Jensen, Henrik Holm ^b  

^a Centre of Health Economics Research (COHERE)   (Denmark)

^b Incentive ^*  (Denmark)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Diabetes; Disutility; Health related quality of life; Hypoglycaemia; Time trade off

Indexed keywords

ANTIDIABETIC AGENT;

AGED; DIABETES MELLITUS; FEMALE; HEALTH STATUS; HEALTH SURVEY; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NONPARAMETRIC TEST; PSYCHOLOGY; QUALITY OF LIFE;

AGED; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH STATUS; HEALTH SURVEYS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; QUALITY OF LIFE; STATISTICS, NONPARAMETRIC;

EID: 84912008556     PISSN: 09629343     EISSN: 15732649     Source Type: Journal    
DOI: 10.1007/s11136-014-0712-x     Document Type: Article

References (30)

1. UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet,352, 837–853.
2. Hepburn, D. A. (1993). Symptoms of hypoglycemia. In B. M. Frier (Ed.), Hypoglycemia and diabetes: Clinical and physiological aspects. London: Edward Arnold.
3. American Diabetes Association Workgroup on Hypoglycaemia. (2005). Defining and reporting hypoglycemia in diabetes: A report from the American Diabetes Association workgroup on hypoglycemia. Diabetes Care,28, 1245–1249.
4. Yale, J.-F., Begg, I., Gerstein, H., Houlden, R., Jones, H., Maheux, P., et al. (2002). 2001 Canadian Diabetes Association clinical practice guidelines for the prevention and management of hypoglycemia in diabetes. Canadian Journal of Diabetes,26, 22–35.
5. Donnelly, L. A., Morris, A. D., Frier, B. M., Ellis, J. D., Donnan, P. T., Durrant, R., et al. (2009). Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: A population-based study. Diabetic Medicine,22, 749–755.
6. Fidler, C., Elmelund Christensen, T., & Gillard, S. (2011). Hypoglycemia: An overview of fear of hypoglycemia, quality-of-life, and impact on costs. Journal of Medical Economics,14, 646–655.
7. Alvarez-Guisasola, F., Yin, D. D., Nocea, G., Qiu, Y., & Mavros, P. (2010). Association of hypoglycemic symptoms with patients’ rating of their health-related quality of life state: A cross sectional study. Health and Quality of Life Outcomes,8, 86.
8. Clarke, P., Gray, A., & Holman, R. (2002). Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Medical Decision Making,22, 340–349.
9. Weinstein, M. C., Torrance, G., & McGuire, A. (2009). QALYs: The basics. Value in Health,12(Suppl 1), S5–S9.
10. National Institute for Health and Clinical Excellence. (2013). Guide to the methods of technology appraisal. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed May 2013.
11. National Institute for Health and Care Excellence. (2013). Process and methods guides. Guide to methods of technology appraisal. http://www.nice.org.uk/media/D45/1E/GuideToMethodsTechnologyAppraisal2013.pdf. Accessed Aug 2013.
12. CADTH. (2006). HTA Guidelines for the economic evaluation of health technologies: Canada 3rd Edition. http://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf. Accessed Aug 2013.
13. Scottish Medicines Consortium. (2013). Guidance to manufacturers for completion of new product assessment form (NPAF). http://www.scottishmedicines.org.uk/Submission_Process/Submission_Guidance_and_Templates_for_Industry/Templates-Guidance-for-Submission/Templates-Guidance-for-Submission. Accessed Aug 2013.
14. TLV. (2013). Läkemedelsförmånsnämndens allmänna råd. Läkemedelsförmånsnämndens allmänna råd om ekonomiska utvärderingar. http://www.tlv.se/Upload/Lagar_och_foreskrifter/LAG-lfnar-2003-2.pdf. Accessed Aug 2013.
15. Evans, M., Khunti, K., Mamdani, M., Galbo-Jørgensen, C., Gundgaard, J., Bøgelund, M., et al. (2013). Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: A time trade-off survey in five countries. Health and Quality of Life Outcomes,11, 90. doi:10.1186/1477-7525-11-90.
16. Efron, B., & Tibshirani, R. (1993). An introduction to the bootstrap. Boca Raton, FL: Chapman and Hall/CRC.
17. Marrett, E., Radican, L., Davies, M. J., & Zhang, Q. (2011). Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: A survey study. BMC Research Notes,4, 251. doi:10.1186/1756-0500-4-251.
18. Levy, A. R., Christensen, T. L., & Johnson, J. A. (2008). Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health and Quality of Life Outcomes,6, 73.
19. Allen, K. V., & Frier, B. M. (2003). Nocturnal hypoglycemia: Clinical manifestations and therapeutic strategies toward prevention. Endocrine Practice,9, 530–543.
20. Vexiau, P., Mavros, P., Krishnarajah, G., Lyu, R., & Yin, D. (2008). Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes, Obesity and Metabolism,10(Suppl. 1), 16–24.
21. Greene, W. H. (1999). Econometric analysis (4th ed.). Upper Saddle River, New Jersey: Prentice Hall.
22. Briggs, A., Claxton, K., & Sculpher, M. (2006). Decision modelling for health economic evaluation. UK: Oxford.
23. Wooldridge, J. M. (2012). Introductory econometric analysis: A modern approach south-western/CENGAGE learning (4th ed.). UK: Hampshire.
24. Harris, S. B., Khunti, K., Landin-Olsson, M., Galbo-Jørgensen, C. B., Bøgelund, M., Chubb, M., et al. (2013). Descriptions of health states associated with increasing severity and frequency of hypoglycemia: A patient-level perspective. Patient Preference and Adherence,16, 925–936.
25. Currie, C. J., Morgan, C. L., Poole, C. D., Sharplin, P., Lammert, M., & McEwan, P. (2006). Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Current Medical Research and Opinion,22, 1523–1534.
26. Drummond, M. (2001). Introducing economic and quality of life measurements into clinical studies. Annals of Medicine,33, 344–349.
27. Walters, S. J., & Brazier, J. E. (2005). Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Quality of Life Research,14, 1523–1532.
28. Luo, N., Johnson, J. A., & Coons, S. J. (2010). Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments. Medical Care,48, 365–371.
29. Feeny, D. (2005). Preference-based measures: Utility and quality-adjusted life years, Chapter 6.2. In P. Fayers & R. Hays (Eds.), Assessing quality of life in clinical trials (2nd ed., pp. 405–429). Oxford: Oxford University Press.
30. Brod, M., Christensen, T., Thomsen, T. L., & Bushnell, D. M. (2011). The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value in Health,14, 665–671.